
News|Poll|March 27, 2015
Have You Heard This (Week's) News?
Author(s)Susan Kweskin
Advertisement
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.
Eylea (aflibercept) injection is also indicated for treatment of which of the following?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
First Oral Film Treatment for Erectile Dysfunction in Men Gains FDA Approval
2
Long-Term Data Support Sustained Bimekizumab Response in Hidradenitis Suppurativa
3
Weekly Dose Podcast: New Obesity Data, Insulin Guidance, and Mental Health Screening
4
Topline Phase 2 Data Show Roflumilast Cream Improves Atopic Dermatitis in Infants as Young as 3 Months
5






























































































































